Amlitelimab, Placebo clinical trials

A randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to assess the efficacy, safety, and tolerability of subcutaneous amlitelimab in adult participants with moderate-to-severe asthma. DRI17509

This study is testing a new medicine, amlitelimab, for adults with moderate to severe asthma. We want to see if it can reduce severe asthma attacks and improve breathing and quality of life over 48 weeks.